The epidemiology of hepatitis B virus infection in Korea
2
조회
0
다운로드
24
인용
0
참고문헌
키워드
초록
The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The risk factors for chronic hepatitis B-related liver disease differ according to HBV endemicity, hepatitis B e-antigen seropositivity, and viral load. It is important to identify these risk factors and start antiviral treatment at an appropriate time according to current guidelines. The most crucial step in reducing HBV infection is prevention in infancy or early childhood, as infection at an early stage may lead to chronicity. South Korea was formerly an HBV-endemic area, but the epidemiology of HBV infection was changed by the introduction of vaccination in 1983 and nationwide immunization in 1995. The government and the private sector made efforts to reduce the prevalence of HBV infection, and Korea is on target to meet the World Health Organization goal of eliminating viral hepatitis by 2030. To eliminate hepatitis worldwide, the costs of antiviral treatment to prevent perinatal HBV transmission in pregnant women with high viremia should be covered by a national program, and strategies to reduce the prevalence of HBV infection in immigrant populations are needed.
Abstract
The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The risk factors for chronic hepatitis B-related liver disease differ according to HBV endemicity, hepatitis B e-antigen seropositivity, and viral load. It is important to identify these risk factors and start antiviral treatment at an appropriate time according to current guidelines. The most crucial step in reducing HBV infection is prevention in infancy or early childhood, as infection at an early stage may lead to chronicity. South Korea was formerly an HBV-endemic area, but the epidemiology of HBV infection was changed by the introduction of vaccination in 1983 and nationwide immunization in 1995. The government and the private sector made efforts to reduce the prevalence of HBV infection, and Korea is on target to meet the World Health Organization goal of eliminating viral hepatitis by 2030. To eliminate hepatitis worldwide, the costs of antiviral treatment to prevent perinatal HBV transmission in pregnant women with high viremia should be covered by a national program, and strategies to reduce the prevalence of HBV infection in immigrant populations are needed.
참고문헌 (50)
- "Korea National Health and Nutrition Examination Survey (KNHANES)2016" (2016)[URL]
- Cho EJ, "Current status and strategies for hepatitis B control in Korea", Clin Mol Hepatol, 23, pp.205~211 (2017)
- 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회
- Global Hepatitis Report 2017, "World Health Organization", WHO, ~ (2017)
- "Hepatitis B vaccines: WHO position paper (July 2017)" (2019)[URL]
- Park NH, "Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period", Intervirology, 53, pp.20~28 (2010)
- Lee HS, "Etiology and outcome of acute viral hepatitis in Korean adults", J Korean Med Sci, 5, pp.149~154 (1990)
- 정숙향, "국내 A형간염의 현황과 백신 적응증", 대한소화기학회지, 51(6), pp.331~337 (2008), 대한소화기학회
- 임형준, "2000년대 초기의 국내 급성 B형 간염 발생 양상의 변화", 대한내과학회지, 69(6), pp.601~607 (2005), 대한내과학회
- 최혜진, "Clinical features of acute viral hepatitis B in Korea: a multi-center study", Clinical and Molecular Hepatology, 17(4), pp.307~312 (2011), 대한간학회
- Yotsuyanagi H, "Persistent viremia after recovery from self-limited acute hepatitis B", Hepatology, 27, pp.1377~1382 (1998)
- Rehermann B, "The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response", Nat Med, 2, pp.1104~1108 (1996)
- Marusawa H, "Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen", Hepatology, 31, pp.488~495 (2000)
- Yuki N, "Long-term histologic and virologic outcomes of acute self-limited hepatitis B", Hepatology, 37, pp.1172~1179 (2003)
- Pattullo V, "Prevention of hepatitis B reactivation in the setting of immunosuppression", Clin Mol Hepatol, 22, pp.219~237 (2016)
- European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
- Villeneuve JP, "A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal", Gastroenterology, 106, pp.1000~1005 (1994)
- Fattovich G, "Natural history of chronic hepatitis B : special emphasis on disease progression and prognostic factors", J Hepatol, 48, pp.335~352 (2008)
- Fattovich G, "Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis", Hepatology, 21, pp.77~82 (1995)
- Liaw YF, "Natural course after the development of cirrhosis in patients with chronic type B hepatitis : a prospective study", Liver, 9, pp.235~241 (1989)
- Yoon SK, "Status of hepatocellular carcinoma in South Korea", Chin Clin Oncol, 2, pp.39~ (2013)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
- Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
- Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study", Gastroenterology, 147, pp.143~151 (2014)
- Kim CY, "Natural history and survival rate of chronic liver diseases in Korea : 20years prospective analysis", Korean J Med, 46, pp.168~180 (1994)
- Chiang CJ, "Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan", Hepatology, 61, pp.1154~1162 (2015)
- Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population", Hepatology, 66, pp.1454~1463 (2017)
- Yim SY, "The management and prognosis of patients with hepatocellular carcinoma:what has changed in 20 years?", Liver Int, 36, pp.445~453 (2016)
- Yim SY, "Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B", J Clin Gastroenterol, 49, pp.61~68 (2015)
- Lin CL, "New perspectives of biomarkers for the management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.423~431 (2016)
- Lin CL, "What can we learn from hepatitis B virus clinical cohorts?", Liver Int, (35 Suppl 1), pp.91~99 (2015)
- Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
- Tseng TC, "Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads", Hepatology, 57, pp.441~450 (2013)
- Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
- Simonetti J, "Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus", Hepatology, 51, pp.1531~1537 (2010)
- Zhu L, "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients : a population-based prospective cohort", J Viral Hepat, 25, pp.1588~1598 (2018)
- Ahn SH, "Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance", J Hepatol, 42, pp.188~194 (2005)
- Park YM, "Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea : a retrospective longitudinal study", World J Gastroenterol, 22, pp.9836~9843 (2016)
- Kim GA, "Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients : a need for surveillance", J Hepatol, 62, pp.1092~1099 (2015)
- Kim JH, "HBsAg seroclearance in chronic hepatitis B : implications for hepatocellular carcinoma", J Clin Gastroenterol, 45, pp.64~68 (2011)
- Yang BM, "The societal burden of HBV-related disease : South Korea", Dig Dis Sci, 55, pp.784~793 (2010)
- Ganem D, "Hepatitis B virus infection : natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
- Cho HY, "Immunization decision-making in the Republic of Korea: the structure and functioning of the Korea Advisory Committee on Immunization Practices", Vaccine, (28 Suppl 1), pp.A91~A95 (2010)
- "Meeting report: the third hepatitis B expert resource panel consultation" (2015)[URL]
- Brown RS Jr, "Antiviral therapy in chronic hepatitis B viral infection during pregnancy : a systematic review and meta-analysis", Hepatology, 63, pp.319~333 (2016)
- Wen WH, "Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection", Hepatology, 64, pp.1451~1461 (2016)
- Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
- Lin Y, "Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads", Sci Rep, 8, pp.15514~ (2018)
- Hyun MH, "Systematic review with meta-analysis : the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus", Aliment Pharmacol Ther, 45, pp.1493~1505 (2017)